An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review

References

• Abbas, S. E., Aly, E. I., Awadallah, F. M., & Mahmoud, W. R. (2015). 4‐Substituted‐1‐phenyl‐1H‐pyrazolo [3,4‐d] pyrimidine derivatives: Design, synthesis, antitumor and EGFR tyrosine kinase inhibitory activity. Chemical Biology & Drug Design, 85(5), 608–622. https://doi.org/10.1111/cbdd.12451
   PubMed Web of Science ®Google Scholar
• Abdelgawad, M. A., Bakr, R. B., Alkhoja, O. A., & Mohamed, W. R. (2016). Design, synthesis and antitumor activity of novel pyrazolo[3,4-d] pyrimidine derivatives as EGFR-TK inhibitors. Bioorganic Chemistry, 66, 88–96. https://doi.org/10.1016/j.bioorg.2016.03.011
   PubMed Web of Science ®Google Scholar
• Abdellatif, K. R., & Bakr, R. B. (2021). Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment. Medicinal Chemistry Research, 30(1), 31–49. https://doi.org/10.1007/s00044-020-02656-8
   Web of Science ®Google Scholar
• Antonini, I., Polucci, P., Magnano, A., Sparapani, S., & Martelli, S. (2004). Rational design, synthesis, and biological evaluation of bis (pyrimido [5, 6, 1-de] acridines) and bis (pyrazolo [3, 4, 5-kl] acridine-5-carboxamides) as new anticancer agents. Journal of Medicinal Chemistry, 47(21), 5244–5250. https://doi.org/10.1021/jm049706k
   PubMed Web of Science ®Google Scholar
• Bhatia, P., Sharma, V., Alam, O., Manaithiya, A., Alam, P., Alam, M. T., Imran., & M., Kahksha. (2020). Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019). European Journal of Medicinal Chemistry, 204, 112640. https://doi.org/10.1016/j.ejmech.2020.112640
   PubMed Web of Science ®Google Scholar
• Carpenter, G., & Cohen, S. (1979). Epidermal growth factor. Annual Review of Biochemistry, 48, 193–216. https://doi.org/10.1146/annurev.bi.48.070179.001205
   PubMed Web of Science ®Google Scholar
• Dhiwar, P. S., Matada, G. S., Raghavendra, N. M., Ghara, A., Singh, E., Abbas, N., Andhale, G. S., Shenoy, G. P., & Sasmal, P. (2022). Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer. Medicinal Chemistry Research, 31(9), 1401–1413. https://doi.org/10.1007/s00044-022-02934-7
   Web of Science ®Google Scholar
• El-Hamouly, W. S., El-Khamry, A. M., & Abbas, E. M. (2007). Synthesis of new 4-aryl-isoxazolo [5, 4-d] pyrimidin-6-one (thione) and 4-aryl-pyrazolo [3, 4-d]-pyrimidin-6-one derivatives of potential antihypertensive activity. ChemInform, 38(3), 2091–2098. https://doi.org/10.1002/chin.200703140
   Google Scholar
• El-Moghazy, S. M., Ibrahim, D. A., Abdelgawad, N. M., Farag, N. A., & El-Khouly, A. S. (2011). Design, synthesis and biological evaluation of novel pyrimido[4,5-d] pyrimidine CDK2 inhibitors as anti-tumor agents. Scientia Pharmaceutica, 79(3), 429–447. https://doi.org/10.3797/scipharm.1103-16
   PubMedGoogle Scholar
• Engel, J., Smith, S., Lategahn, J., Tumbrink, H. L., Goebel, L., Becker, C., Hennes, E., Keul, M., Unger, A., Müller, H., Baumann, M., Schultz-Fademrecht, C., Günther, G., Hengstler, J. G., & Rauh, D. (2017). Structure-guided development of covalent and mutant-selective pyrazolopyrimidines to target T790M drug resistance in epidermal growth factor receptor. Journal of Medicinal Chemistry, 60(18), 7725–7744. https://doi.org/10.1021/acs.jmedchem.7b00515
   PubMed Web of Science ®Google Scholar
• Gan, H. K., Kaye, A. H., & Luwor, R. B. (2009). The EGFRvIII variant in glioblastoma multiforme. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia, 16(6), 748–754. https://doi.org/10.1016/j.jocn.2008.12.005
   PubMed Web of Science ®Google Scholar
• Garg, G., Pande, M., Agrawal, A., Li, J., & Kumar, R. (2016). Investigation of 4-amino-5-alkynylpyrimidine-2 (1H)-ones as anti-mycobacterial agents. Bioorganic and Medicinal Chemistry, 24(8), 771–777.
   Web of Science ®Google Scholar
• Giaccone, G. (2004). The role of gefitinib in lung cancer treatment. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 10(12 Pt 2), 4233s–4237s. https://doi.org/10.1158/1078-0432.CCR-040005
   PubMed Web of Science ®Google Scholar
• Gschwind, A., Fischer, O. M., & Ullrich, A. (2004). The discovery of receptors tyrosine kinases: Targets for cancer therapy. Nature Reviews. Cancer, 4(5), 361–370. https://doi.org/10.1038/nrc1360
   PubMed Web of Science ®Google Scholar
• Hanan, E. J., Baumgardner, M., Bryan, M. C., Chen, Y., Eigenbrot, C., Fan, P., Gu, X.-H., La, H., Malek, S., Purkey, H. E., Schaefer, G., Schmidt, S., Sideris, S., Yen, I., Yu, C., & Heffron, T. P. (2016). 4-Aminoindazolyl-dihydrofuro [3,4-d] pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters, 26(2), 534–539. https://doi.org/10.1016/j.bmcl.2015.11.078
   PubMed Web of Science ®Google Scholar
• Hao, Y., Lyu, J., Qu, R., Tong, Y., Sun, D., Feng, F., Tong, L., Yang, T., Zhao, Z., Zhu, L., Ding, J., Xu, Y., Xie, H., & Li, H. (2018). Design, synthesis, and biological evaluation of pyrimido[4, 5-d]pyrimidine-2, 4 (1H, 3 H)-diones as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation. Journal of Medicinal Chemistry, 61(13), 5609–5622. https://doi.org/10.1021/acs.jmedchem.8b00346
   PubMed Web of Science ®Google Scholar
• Hossam, M., Lasheen, D. S., Ismail, N. S., Esmat, A., Mansour, A. M., Singab, A. N., & Abouzid, K. A. (2018). Discovery of anilino-furo[2,3-d] pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity. European Journal of Medicinal Chemistry, 144, 330–348. https://doi.org/10.1016/j.ejmech.2017.12.022
   PubMed Web of Science ®Google Scholar
• Huang, Y. Y., Wang, L. Y., Chang, C. H., Kuo, Y. H., Kaneko, K., Takayama, H., Kimura, M., Juang, S. H., & Wong, F. F. (2012). One-pot synthesis and antiproliferative evaluation of pyrazolo [3,4-d] pyrimidine derivatives. Tetrahedron, 68(47), 9658–9664. https://doi.org/10.1016/j.tet.2012.09.054
   Web of Science ®Google Scholar
• Hubbard, R. D., Dickerson, S. H., Emerson, H. K., Griffin, R. J., Reno, M. J., Hornberger, K. R., Rusnak, D. W., Wood, E. R., Uehling, D. E., & Waterson, A. G. (2008). Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno [3,2-d] pyrimidines. Bioorganic & Medicinal Chemistry Letters, 18(21), 5738–5740. https://doi.org/10.1016/j.bmcl.2008.09.090
   PubMed Web of Science ®Google Scholar
• Ishikawa, T., Seto, M., Banno, H., Kawakita, Y., Oorui, M., Taniguchi, T., Ohta, Y., Tamura, T., Nakayama, A., Miki, H., Kamiguchi, H., Tanaka, T., Habuka, N., Sogabe, S., Yano, J., Aertgeerts, K., & Kamiyama, K. (2011). Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo [3,2-d] pyrimidine scaffold. Journal of Medicinal Chemistry, 54(23), 8030–8050. https://doi.org/10.1021/jm2008634
   PubMed Web of Science ®Google Scholar
• Ji, X., Peng, T., Zhang, X., Li, J., Yang, W., Tong, L., Qu, R., Jiang, H., Ding, J., Xie, H., & Liu, H. (2014). Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno [2,3-d] pyrimidines as irreversible epidermal growth factor receptor inhibitors. Bioorganic & Medicinal Chemistry, 22(7), 2366–2378. https://doi.org/10.1016/j.bmc.2014.01.035
   PubMed Web of Science ®Google Scholar
• Kamath, S., & Buolamwini, J. K. (2006). Targeting EGFR and HER‐2 receptor tyrosine kinases for cancer drug discovery and development. Medicinal Research Reviews, 26(5), 569–594. https://doi.org/10.1002/med.20070
   PubMed Web of Science ®Google Scholar
• Kaspersen, S. J., Sørum, C., Willassen, V., Fuglseth, E., Kjøbli, E., Bjørkøy, G., Sundby, E., & Hoff, B. H. (2011). Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo [2,3-d] pyrimidine-4-amines. European Journal of Medicinal Chemistry, 46(12), 6002–6014. https://doi.org/10.1016/j.ejmech.2011.10.012
   PubMed Web of Science ®Google Scholar
• Lamie, P. F., El-Kalaawy, A. M., Latif, N. S., Rashed, L. A., & Philoppes, J. N. (2021). Pyrazolo [3, 4-d] pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents. European Journal of Medicinal Chemistry, 214, 113222. https://doi.org/10.1016/j.ejmech.2021.113222
   PubMed Web of Science ®Google Scholar
• Lin, S.-Y., Chang Hsu, Y., Peng, Y.-H., Ke, Y.-Y., Lin, W.-H., Sun, H.-Y., Shiao, H.-Y., Kuo, F.-M., Chen, P.-Y., Lien, T.-W., Chen, C.-H., Chu, C.-Y., Wang, S.-Y., Yeh, K.-C., Chen, C.-P., Hsu, T.-A., Wu, S.-Y., Yeh, T.-K., Chen, C.-T., & Hsieh, H.-P. (2019). Discovery of a furanopyrimidine-based epidermal growth factor receptor inhibitor (DBPR112) as a clinical candidate for the treatment of non-small cell lung cancer. Journal of Medicinal Chemistry, 62(22), 10108–10123. https://doi.org/10.1021/acs.jmedchem.9b00722
   PubMed Web of Science ®Google Scholar
• Lin, R., Johnson, S. G., Connolly, P. J., Wetter, S. K., Binnun, E., Hughes, T. V., Murray, W. V., Pandey, N. B., Moreno-Mazza, S. J., Adams, M., Fuentes-Pesquera, A. R., & Middleton, S. A. (2009). Synthesis and evaluation of 2, 7-diamino-thiazolo [4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 19(8), 2333–2337. https://doi.org/10.1016/j.bmcl.2009.02.067
   PubMed Web of Science ®Google Scholar
• Liu, Q., Yu, S., Zhao, W., Qin, S., Chu, Q., & Wu, K. (2018). EGFR-TKIs resistance via EGFR-independent signaling pathways. Molecular Cancer, 17(1), 1–9. https://doi.org/10.1186/s12943-018-0793-1
   PubMedGoogle Scholar
• Maher, M., Kassab, A. E., Zaher, A. F., & Mahmoud, Z. (2019). Novel pyrazolo [3,4-d] pyrimidines: Design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis. Journal of Enzyme Inhibition and Medicinal Chemistry, 34(1), 532–546. https://doi.org/10.1080/14756366.2018.1564046
   PubMed Web of Science ®Google Scholar
• McGuire, A., Brown, J. A., Malone, C., McLaughlin, R., & Kerin, M. J. (2015). Effects of age on the detection and management of breast cancer. Cancers, 7(2), 908–929. https://doi.org/10.3390/cancers7020815
   PubMed Web of Science ®Google Scholar
• Merlino, G. T., Xu, Y. H., Richert, N., Clark, A. J., Ishii, S., Banks-Schlegel, S., & Pastan, I. (1985). Elevated epidermal growth factor receptor gene copy number and expression in a squamous carcinoma cell line. The Journal of Clinical Investigation, 75(3), 1077–1079. https://doi.org/10.1172/JCI111770
   PubMed Web of Science ®Google Scholar
• Milik, S. N., Abdel-Aziz, A. K., Lasheen, D. S., Serya, R. A., Minucci, S., & Abouzid, K. A. (2018). Surmounting the resistance against EGFR inhibitors through the development of thieno [2,3-d] pyrimidine-based dual EGFR/HER2 inhibitors. European Journal of Medicinal Chemistry, 155, 316–336. https://doi.org/10.1016/j.ejmech.2018.06.011
   PubMed Web of Science ®Google Scholar
• Montemurro, F., Valabrega, G., & Aglietta, M. (2007). Lapatinib: A dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opinion on Biological Therapy, 7(2), 257–268. https://doi.org/10.1517/14712598.7.2.257
   PubMed Web of Science ®Google Scholar
• Murtuza, A., Bulbul, A., Shen, J. P., Keshavarzian, P., Woodward, B. D., Lopez-Diaz, F. J., Lippman, S. M., & Husain, H. (2019). Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Research, 79(4), 689–698. https://doi.org/10.1158/0008-5472.CAN-18-1281
   PubMed Web of Science ®Google Scholar
• Nassar, I. F., Atta-Allah, S. R., & Elgazwy, A.-S S. H. (2015). A convenient synthesis and molecular modeling study of novel pyrazolo [3,4-d] pyrimidine and pyrazole derivatives as anti-tumor agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 30(3), 396–405. https://doi.org/10.3109/14756366.2014.940936
   PubMed Web of Science ®Google Scholar
• Okasha, R. M., Albalawi, F. F., Afifi, T. H., Fouda, A. M., Al-Dies, A. A., & El-Agrody, A. M. (2016). Structural characterization and antimicrobial activities of 7 H-Benzo [h] chromeno [2,3-d] pyrimidine and 14 H-benzo [h] chromeno [3,2-e][1,2,4] triazolo [1,5-c] pyrimidine derivatives. Molecules, 21(11), 1450. https://doi.org/10.3390/molecules21111450
   PubMed Web of Science ®Google Scholar
• Othman, E. M., Bekhit, A. A., Anany, M. A., Dandekar, T., Ragab, H. M., & Wahid, A. (2021). Design, synthesis, and anticancer screening for repurposed pyrazolo [3,4-d] pyrimidine derivatives on four mammalian cancer cell lines. Molecules, 26(10), 2961. https://doi.org/10.3390/molecules26102961
   PubMed Web of Science ®Google Scholar
• Park, S., Ku, B. M., Jung, H. A., Sun, J. M., Ahn, J. S., Lee, S. H., Park, K., & Ahn, M. J. (2020). EGFR C797S as a resistance mechanism of lazertinib in non-small cell lung cancer with EGFR T790M mutation. Cancer Research and Treatment, 52(4), 1288–1290. https://doi.org/10.4143/crt.2020.278
   PubMed Web of Science ®Google Scholar
• Parsa, N. (2012). Environmental factors inducing human cancers. Iranian Journal of Public Health, 41(11), 1–9.
   PubMed Web of Science ®Google Scholar
• Rashad, A. E., & Ali, M. A. (2006). Synthesis and antiviral screening of some thieno [2, 3-d] pyrimidine nucleosides. Nucleosides, Nucleotides & Nucleic Acids, 25(1), 17–28. https://doi.org/10.1080/15257770500377730
   PubMed Web of Science ®Google Scholar
• Rashad, A. E., Hegab, M. I., Abdel-Megeid, R. E., Fathalla, N., & Abdel-Megeid, F. M. (2009). Synthesis and anti-HSV-1 evaluation of some pyrazoles and fused pyrazolopyrimidines. European Journal of Medicinal Chemistry, 44(8), 3285–3292. https://doi.org/10.1016/j.ejmech.2009.02.012
   PubMed Web of Science ®Google Scholar
• Rimawi, M. F., Shetty, P. B., Weiss, H. L., Schiff, R., Osborne, C. K., Chamness, G. C., & Elledge, R. M. (2010). Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer, 116(5), 1234–1242. https://doi.org/10.1002/cncr.24816
   PubMed Web of Science ®Google Scholar
• Shigematsu, H., & Gazdar, A. F. (2006). Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. International Journal of Cancer, 118(2), 257–262. https://doi.org/10.1002/ijc.21496
   PubMed Web of Science ®Google Scholar
• Showalter, H. H., Bridges, A. J., Zhou, H., Sercel, A. D., McMichael, A., & Fry, D. W. (1999). Tyrosine kinase inhibitors. 16. 6, 5, 6-tricyclic benzothieno [3,2-d] pyrimidines and pyrimido [5, 4-b]-and-[4,5-b] indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase. Journal of Medicinal Chemistry, 42(26), 5464–5474. https://doi.org/10.1021/jm9903949
   PubMed Web of Science ®Google Scholar
• Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer statistics, 2015. CA: A Cancer Journal for Clinicians, 65(1), 5–29. https://doi.org/10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Singh, B., Guru, S. K., Kour, S., Jain, S. K., Sharma, R., Sharma, P. R., Singh, S. K., Bhushan, S., Bharate, S. B., & Vishwakarma, R. A. (2013). Synthesis, antiproliferative and apoptosis-inducing activity of thiazolo [5, 4-d] pyrimidines. European Journal of Medicinal Chemistry, 70, 864–874. https://doi.org/10.1016/j.ejmech.2013.10.039
   PubMed Web of Science ®Google Scholar
• Smaill, J. B., Showalter, H. D., Zhou, H., Bridges, A. J., McNamara, D. J., Fry, D. W., Nelson, J. M., Sherwood, V., Vincent, P. W., Roberts, B. J., Elliott, W. L., & Denny, W. A. (2001). Tyrosine kinase inhibitors. 18. 6-substituted 4-anilinoquinazolines and 4-anilinopyrido [3,4-d] pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. Journal of Medicinal Chemistry, 44(3), 429–440. https://doi.org/10.1021/jm000372i
   PubMed Web of Science ®Google Scholar
• Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W.-C., Gray, J. E., Ramalingam, S. S., … FLAURA Investigators. (2018). Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. The New England Journal of Medicine, 378(2), 113–125. https://doi.org/10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Spasov, A. A., Babkov, D. A., Sysoeva, V. A., Litvinov, R. A., Shamshina, D. D., Ulomsky, E. N., Savateev, K. V., Fedotov, V. V., Slepukhin, P. A., Chupakhin, O. N., Charushin, V. N., & Rusinov, V. L. (2017). 6‐Nitroazolo [1,5‐a] pyrimidin‐7(4H)‐ones as antidiabetic agents. Archiv der Pharmazie, 350(12), 1700226. https://doi.org/10.1002/ardp.201700226
   Web of Science ®Google Scholar
• Sreerama, R., Kumar, N. M., Nukala, S. K., Sucharitha, E. R., Babu, H. R., & Narsimha, S. (2021). Synthesis and biological evaluation of novel 1, 2, 3-triazole based pyrido [4,3-d] pyrimidines as potent anticancer and EGFR inhibitors. Russian Journal of General Chemistry, 91(12), 2515–2521. https://doi.org/10.1134/S1070363221120227
   Web of Science ®Google Scholar
• Virgilio, A., Spano, D., Esposito, V., Di Dato, V., Citarella, G., Marino, N., Maffia, V., De Martino, D., De Antonellis, P., Galeone, A., & Zollo, M. (2012). Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancer. European Journal of Medicinal Chemistry, 57, 41–50. https://doi.org/10.1016/j.ejmech.2012.08.020
   PubMed Web of Science ®Google Scholar
• Wang, H., Pan, R., Zhang, X., Si, X., Wang, M., & Zhang, L. (2020). Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib. Thoracic Cancer, 11(3), 594–602. https://doi.org/10.1111/1759-7714.13302
   PubMed Web of Science ®Google Scholar
• Wee, P., & Wang, Z. (2017). Epidermal growth factor receptor cell proliferation signaling pathways. Cancers, 9(5), 52. https://doi.org/10.3390/cancers9050052
   PubMed Web of Science ®Google Scholar
• Wind, S., Schnell, D., Ebner, T., Freiwald, M., & Stopfer, P. (2017). Clinical pharmacokinetics and pharmacodynamics of afatinib. Clinical Pharmacokinetics, 56(3), 235–250. https://doi.org/10.1007/s40262-016-0440-1
   PubMed Web of Science ®Google Scholar
• Xia, Z., Huang, R., Zhou, X., Chai, Y., Chen, H., Ma, L., Yu, Q., Li, Y., Li, W., & He, Y. (2021). The synthesis and bioactivity of pyrrolo [2,3-d] pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations. European Journal of Medicinal Chemistry, 224, 113711. https://doi.org/10.1016/j.ejmech.2021.113711
   PubMed Web of Science ®Google Scholar
• Xu, S., Xu, T., Zhang, L., Zhang, Z., Luo, J., Liu, Y., Lu, X., Tu, Z., Ren, X., & Ding, K. (2013). Design, synthesis, and biological evaluation of 2-oxo-3, 4-dihydropyrimido [4,5-d] pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties. Journal of Medicinal Chemistry, 56(21), 8803–8813. https://doi.org/10.1021/jm4012388
   PubMed Web of Science ®Google Scholar
• Zhang, W., Chen, Y., & Li, D. (2017). Drug-target interaction prediction through label propagation with linear neighborhood information. Molecules, 22(12), 2056. https://doi.org/10.3390/molecules22122056
   PubMed Web of Science ®Google Scholar
• Zhang, H., Wang, J., Shen, Y., Wang, H. Y., Duan, W. M., Zhao, H. Y., Hei, Y. Y., Xin, M., Cao, Y. X., & Zhang, S. Q. (2018). Discovery of 2, 4, 6-trisubstitued pyrido [3, 4-d] pyrimidine derivatives as new EGFR-TKIs. European Journal of Medicinal Chemistry, 148, 221–237. https://doi.org/10.1016/j.ejmech.2018.02.051
   PubMed Web of Science ®Google Scholar